The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's Wegovy, whose patent for semaglutide in a few markets expires in 2026.
Researchers have discovered that drugs like Ozempic for diabetes and obesity also improve alcohol use disorders and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results